|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||2.90 / 14.40|
At 12 Months SGX942 Found to be Safe and Well Tolerated with Multiple Potential Ancillary Benefits
Patent describes application of ThermoVax® with RiVax®
Trial Targeted to Begin in Second Quarter of 2017
Highlighted by Revenues of $10.4 Million
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.